KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to -$1.2 billion.

  • Vertex Pharmaceuticals' Cash from Financing Activities fell 19793.55% to -$1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 billion, marking a year-over-year decrease of 11051.17%. This contributed to the annual value of -$1.5 billion for FY2024, which is 16590.18% down from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Cash from Financing Activities stood at -$1.2 billion, which was down 19793.55% from -$349.2 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Cash from Financing Activities ranged from a high of $47.7 million in Q2 2022 and a low of -$1.2 billion during Q3 2025
  • Moreover, its 5-year median value for Cash from Financing Activities was -$336.2 million (2021), whereas its average is -$304.6 million.
  • In the last 5 years, Vertex Pharmaceuticals' Cash from Financing Activities soared by 11195.72% in 2022 and then plummeted by 217283.24% in 2024.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Cash from Financing Activities stood at -$336.2 million in 2021, then skyrocketed by 111.96% to $40.2 million in 2022, then tumbled by 398.01% to -$119.8 million in 2023, then tumbled by 226.63% to -$391.3 million in 2024, then tumbled by 195.04% to -$1.2 billion in 2025.
  • Its Cash from Financing Activities stands at -$1.2 billion for Q3 2025, versus -$349.2 million for Q2 2025 and -$680.4 million for Q1 2025.